←
MetaVia76 posts
MetaVia avatar

MetaVia

@MetaViaTx

MetaVia (NASDAQ: $MTVA) is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, including #obesity and #MASH.

◷ Joined February 2026▧ 69 Photos and videos
MetaVia avatar
MetaVia@MetaViaTx·Nov 17

Previously reported Phase 1 Part 3B interim data demonstrated a statistically significant 68.1% placebo-adjusted reduction in liver fat, alongside 13.5% placebo-adjusted weight loss and improvements in glycemic control. Read more: bit.ly/4iOmgvC $MTVA

0:22
MetaVia avatar
MetaVia@MetaViaTx·Nov 17

MetaVia expects to report full Phase 1 Parts 3A and 3B data in the first quarter of 2027 and is preparing a 48-week Phase 2 study of DA-1726 in MetALD and ALD, targeted to begin in the second half of 2027. Read more: bit.ly/4iOmgvC $MTVA

0:22
MetaVia avatar
MetaVia@MetaViaTx·Nov 17

MetaVia President and CEO Hyung Heon Kim comments on the encouraging preliminary safety and tolerability observations seen in the Phase 1 Part 3A study of DA-1726, and the Company's preparations to advance DA-1726 into Phase 2 development: bit.ly/4iOmgvC $MTVA

0:34
MetaVia avatar
MetaVia@MetaViaTx·Nov 17

MetaVia today announced that the last patient has completed the final study visit for its Phase 1 clinical trial evaluating DA-1726, a novel GLP-1 (GLP1R)/glucagon (GCGR) dual-receptor agonist. Read more about the study: bit.ly/4iOmgvC $MTVA

0:22
MetaVia avatar
MetaVia@MetaViaTx·Nov 16

"Given our focus on liver-related metabolic disease, we are particularly encouraged that DA-1726 increased both gene expression and protein levels of hepatic Fgf21, a key hormone in the regulation of lipid and carbohydrate metabolism," said H.H. Kim, CEO. bit.ly/4kjL1AU $MTVA

0:20
MetaVia avatar
MetaVia@MetaViaTx·Nov 16

DA-1726 demonstrated statistically significant increases in liver and circulating FGF21 expression, alongside increased expression of genes associated with thermogenesis and energy expenditure. Read more: bit.ly/4kjL1AU #OW2026 $MTVA

0:22
MetaVia avatar
MetaVia@MetaViaTx·Nov 16

MetaVia today announced positive preclinical head-to-head data comparing DA-1726, a novel GLP-1/glucagon dual agonist, with retatrutide, a triple GLP-1R/GIPR/GCGR agonist. Read more about the findings presented at ObesityWeek® 2026: bit.ly/4kjL1AU #OW2026 $MTVA

0:22
MetaVia avatar
MetaVia@MetaViaTx·Nov 13

MetaVia CEO Hyung Heon Kim comments on the clinical progress of DA-1726, highlighting encouraging interim Phase 1 results demonstrating significant reductions in liver fat, body weight and uric acid, and the program’s planned advancement into Phase 2 development for MetALD and ALD in the second half of 2027. Read more: bit.ly/4iGkeO1 $MTVA

0:35
MetaVia avatar
MetaVia@MetaViaTx·Nov 13

MetaVia today announced financial results for the third quarter ended September 30, 2026, and provided a corporate strategic update. For third quarter 2026 highlights and anticipated clinical milestones, visit: bit.ly/4iGkeO1 $MTVA

0:22
MetaVia avatar
MetaVia@MetaViaTx·Nov 12

“These additional findings further strengthen the metabolic profile emerging for DA-1726 and provide another encouraging signal as we advance its development in liver-related cardiometabolic diseases,” said Hyung Heon Kim, President and $MTVA CEO: bit.ly/4jdoc0D

0:34
MetaVia avatar
MetaVia@MetaViaTx·Nov 12

MetaVia is advancing DA-1726 toward a planned 48-week, non-biopsy Phase 2 study in up to 150 subjects with MetALD and ALD in the second half of 2027. Read more: bit.ly/4jdoc0D $MTVA

0:22
MetaVia avatar
MetaVia@MetaViaTx·Nov 12

Phase 1 Part 3B results showed normalization of liver fat in all DA-1726-treated participants with baseline steatosis, 13.5% placebo-adjusted weight loss and improvements in HbA1c. Read more: bit.ly/4jdoc0D $MTVA

0:22
MetaVia avatar
MetaVia@MetaViaTx·Nov 12

Additional Phase 1 Part 3B data further strengthen DA-1726’s liver profile, adding to the previously reported 68.1% placebo-adjusted reduction in liver fat and supporting its potential development in MetALD. Read more: bit.ly/4jdoc0D $MTVA

0:22
MetaVia avatar
MetaVia@MetaViaTx·Nov 12

MetaVia announced additional positive Ph. 1 3B clinical data for DA-1726, demonstrating a statistically significant 1.47 mg/dL placebo-adjusted reduction in uric acid levels after 16 wks (p<0.001), despite normal mean uric acid levels at baseline. bit.ly/4jdoc0D $MTVA

0:22
MetaVia avatar
MetaVia@MetaViaTx·Nov 9

MetaVia announced that an abstract highlighting DA-1726, a novel dual OXM analog targeting both GLP-1 (GLP1R) and glucagon (GCGR) receptors, has been accepted for a poster presentation at ObesityWeek® 2026, held Nov. 14-17th, in DC. bit.ly/4k6qCze #OW2026 $MTVA

0:13
MetaVia avatar
MetaVia@MetaViaTx·Nov 6

MetaVia expects to report full Phase 1 Part 3A and Part 3B data for DA-1726 in Q1 2027, building on encouraging interim findings demonstrating reductions in liver fat, body weight and HbA1c. For full DA-1726 Part 3B interim results, visit: bit.ly/3UvLSUE $MTVA

0:20